Abstract:Background and Aim: Esomeprazole is the S‐isomer of omeprazole, with a stronger acid suppressive effect than omeprazole. This open, randomized crossover study was designed to evaluate the effect of esomeprazole and another proton‐pump inhibitor, rabeprazole, on intragastric pH in healthy Chinese. Methods: Thirty‐six healthy volunteers (26 men and 10 women, aged between 20 and 31 years) were enrolled. Subjects were given either esomeprazole 40 mg ( n = 18) or rabeprazole 10 mg ( n = 18) orally once daily for 5 days during the first dosing period, then the other medicine at the set dosage for the second dosing period. The two periods were separated by a 14‐day washout phase. The doses were chosen according to the State Food and Drug Administration of China for the treatment of acid‐related diseases. Intragastric pH was continuously monitored for 24 h on days 1 and 5 of each dosing period. CYP2C19 genotypes were analyzed to identify the extensive metabolizers (EM) and poor metabolizers (PM). Results: The percentage of time with intragastric pH >4 was significantly higher ( P < 0.001) in subjects receiving esomeprazole than in those receiving rabeprazole in the first 4 h after administration of the first dose (70.65% vs 44.87%), at 24 h on day 1 (73.7% vs 54.8%) and at 24 h on day 5 (84.2% vs 76.2%). The median intragastric pH was also higher in subjects receiving esomeprazole than in those receiving rabeprazole in the first 6 h, day 1 and day 5 ( P ≤ 0.001). The percentage of subjects with intragastric pH >4 for at least 16 h on day 1 (63.9% vs 33.3%) and on day 5 (88.9% vs 61.1%) was higher after administration of esomeprazole than after rabeprazole (both P < 0.05). On genotype analysis, 28 of the subjects were EM and eight were PM. Those who were PM tended to have a higher, albeit not statistically significant, percentage of time with intragastric pH >4 and the median 24‐h intragastric pH than those who were EM. Both drugs were well tolerated. Conclusions: Esomeprazole 40 mg orally once daily is more effective and faster in increasing intragastric pH than rabeprazole 10 mg orally once daily, and thus offers a potential for improved efficacy in acid‐related diseases.

Characterization of Omeprazole Pharmacokinetics in Chinese Extensive and Poor Metabolizers

Evaluation of the Relationship Between Polymorphisms in CYP2C19 and the Single‐dose Pharmacokinetics of Omeprazole in Healthy Chinese Volunteers: A Multicenter Study

Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotype in Healthy Chinese Subjects1

Population Pharmacokinetics of Omeprazole in Healthy Volunteers of Different Nationalities in China by NONMEM

Systematic Review of Influence of CYP2C19 Genetic Polymorphism on Pharmacokinetics of Omeprazole

Effect of Omeprazole on the Hydroxylation of Warfarin Enantiomers in Human: In-Vitro Studies with Liver Microsomes and Cdna-Expressed Cytochrome P450 Isozymes

Effect of esomeprazole on intragastric pH in healthy Chinese with different CYP2C19 genotypes

Effect of Esomeprazole and Rabeprazole on Intragastric Ph in Healthy Chinese: an Open, Randomized Crossover Trial

Improving CYP2C19 phenotyping using stereoselective omeprazole and 5‐hydroxy‐omeprazole metabolic ratios

Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms

Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers

Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole.

Effect of CYP2C19 Polymorphisms on Eradication Rate of H.pylori Infection with Esomeprazole-Based Triple Therapy

The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC-MS/MS and Real Time-PCR methods

Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions

The Influence of Cyp2d6 Activity on the Kinetics of Propafenone Enantiomers in Chinese Subjects

Effects of Cyp2c19 Polymorphism on the Pharmacokinetics of Lansoprazole and Its Main Metabolites in Healthy Chinese Subjects

Pharmacokinetics of Lansoprazole and Its Main Metabolites after Single and Multiple Intravenous Doses in Healthy Chinese Subjects.

Effect of CYP2C19 Genetic Polymorphism on Lansoprazole Pharmacokinetics:A Systematic Review